PASLI disease: Difference between revisions
CSV import |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[File:Proposed_model_for_the_effects_of_activating_substitutions_in_p110δ.png|Proposed model for the effects of activating substitutions in p110δ| | {{SI}} | ||
{{Infobox medical condition | |||
| name = PASLI disease | |||
| image = [[File:Proposed_model_for_the_effects_of_activating_substitutions_in_p110δ.png|250px]] | |||
| caption = Proposed model for the effects of activating substitutions in p110δ | |||
| synonyms = Activated PI3K-δ syndrome (APDS) | |||
| pronounce = | |||
| specialty = [[Immunology]] | |||
| symptoms = Recurrent infections, [[lymphoproliferation]], autoimmunity | |||
| onset = Childhood | |||
| duration = Chronic | |||
| causes = Mutations in the [[PIK3CD]] or [[PIK3R1]] genes | |||
| risks = | |||
| diagnosis = Genetic testing, clinical evaluation | |||
| differential = [[Common variable immunodeficiency]], [[X-linked agammaglobulinemia]] | |||
| prevention = | |||
| treatment = Immunoglobulin replacement therapy, targeted therapies | |||
| medication = [[Sirolimus]], [[Lenalidomide]] | |||
| prognosis = Variable, depending on severity and treatment | |||
| frequency = Rare | |||
| deaths = | |||
}} | |||
'''PASLI disease''' (also known as '''Activated PI3K-δ Syndrome''') is a rare [[primary immunodeficiency]] disorder characterized by mutations in the [[PIK3CD]] or [[PIK3R1]] genes. These mutations lead to hyperactivation of the [[PI3K]] pathway, resulting in immune dysregulation. | |||
==Presentation== | ==Presentation== | ||
Patients with PASLI disease typically present with recurrent [[sinopulmonary infections]], [[lymphadenopathy]], and [[hepatosplenomegaly]]. Other common features include [[autoimmunity]], [[enteropathy]], and an increased risk of [[lymphoma]]. | Patients with PASLI disease typically present with recurrent [[sinopulmonary infections]], [[lymphadenopathy]], and [[hepatosplenomegaly]]. Other common features include [[autoimmunity]], [[enteropathy]], and an increased risk of [[lymphoma]]. | ||
==Genetics== | ==Genetics== | ||
PASLI disease is caused by mutations in the [[PIK3CD]] gene, which encodes the | PASLI disease is caused by mutations in the [[PIK3CD]] gene, which encodes the p110δ catalytic subunit of [[phosphoinositide 3-kinase]], or the [[PIK3R1]] gene, which encodes the p85α regulatory subunit. These mutations result in the constitutive activation of the PI3K pathway, leading to immune cell dysfunction. | ||
==Diagnosis== | ==Diagnosis== | ||
Diagnosis of PASLI disease involves genetic testing to identify mutations in the [[PIK3CD]] or [[PIK3R1]] genes. Additional diagnostic criteria include clinical features such as recurrent infections, lymphoproliferation, and autoimmunity. | Diagnosis of PASLI disease involves genetic testing to identify mutations in the [[PIK3CD]] or [[PIK3R1]] genes. Additional diagnostic criteria include clinical features such as recurrent infections, lymphoproliferation, and autoimmunity. | ||
==Treatment== | ==Treatment== | ||
Treatment for PASLI disease is primarily supportive and includes the use of [[immunoglobulin replacement therapy]], [[antibiotic prophylaxis]], and management of autoimmune complications. Targeted therapies, such as [[PI3K inhibitors]], are being investigated as potential treatments. | Treatment for PASLI disease is primarily supportive and includes the use of [[immunoglobulin replacement therapy]], [[antibiotic prophylaxis]], and management of autoimmune complications. Targeted therapies, such as [[PI3K inhibitors]], are being investigated as potential treatments. | ||
==Prognosis== | ==Prognosis== | ||
The prognosis for individuals with PASLI disease varies depending on the severity of the symptoms and the response to treatment. Early diagnosis and appropriate management are crucial for improving outcomes. | The prognosis for individuals with PASLI disease varies depending on the severity of the symptoms and the response to treatment. Early diagnosis and appropriate management are crucial for improving outcomes. | ||
==See also== | |||
== | |||
* [[Primary immunodeficiency]] | * [[Primary immunodeficiency]] | ||
* [[PIK3CD]] | * [[PIK3CD]] | ||
| Line 23: | Line 39: | ||
* [[Autoimmunity]] | * [[Autoimmunity]] | ||
* [[Lymphoma]] | * [[Lymphoma]] | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Immunodeficiency disorders]] | [[Category:Immunodeficiency disorders]] | ||
[[Category:Rare diseases]] | [[Category:Rare diseases]] | ||
{{Genetic-disorder-stub}} | {{Genetic-disorder-stub}} | ||
Latest revision as of 23:56, 26 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC
| PASLI disease | |
|---|---|
| |
| Synonyms | Activated PI3K-δ syndrome (APDS) |
| Pronounce | |
| Specialty | Immunology |
| Symptoms | Recurrent infections, lymphoproliferation, autoimmunity |
| Complications | N/A |
| Onset | Childhood |
| Duration | Chronic |
| Types | N/A |
| Causes | Mutations in the PIK3CD or PIK3R1 genes |
| Risks | |
| Diagnosis | Genetic testing, clinical evaluation |
| Differential diagnosis | Common variable immunodeficiency, X-linked agammaglobulinemia |
| Prevention | |
| Treatment | Immunoglobulin replacement therapy, targeted therapies |
| Medication | Sirolimus, Lenalidomide |
| Prognosis | Variable, depending on severity and treatment |
| Frequency | Rare |
| Deaths | |
PASLI disease (also known as Activated PI3K-δ Syndrome) is a rare primary immunodeficiency disorder characterized by mutations in the PIK3CD or PIK3R1 genes. These mutations lead to hyperactivation of the PI3K pathway, resulting in immune dysregulation.
Presentation[edit]
Patients with PASLI disease typically present with recurrent sinopulmonary infections, lymphadenopathy, and hepatosplenomegaly. Other common features include autoimmunity, enteropathy, and an increased risk of lymphoma.
Genetics[edit]
PASLI disease is caused by mutations in the PIK3CD gene, which encodes the p110δ catalytic subunit of phosphoinositide 3-kinase, or the PIK3R1 gene, which encodes the p85α regulatory subunit. These mutations result in the constitutive activation of the PI3K pathway, leading to immune cell dysfunction.
Diagnosis[edit]
Diagnosis of PASLI disease involves genetic testing to identify mutations in the PIK3CD or PIK3R1 genes. Additional diagnostic criteria include clinical features such as recurrent infections, lymphoproliferation, and autoimmunity.
Treatment[edit]
Treatment for PASLI disease is primarily supportive and includes the use of immunoglobulin replacement therapy, antibiotic prophylaxis, and management of autoimmune complications. Targeted therapies, such as PI3K inhibitors, are being investigated as potential treatments.
Prognosis[edit]
The prognosis for individuals with PASLI disease varies depending on the severity of the symptoms and the response to treatment. Early diagnosis and appropriate management are crucial for improving outcomes.
See also[edit]
This article is a genetic disorder stub. You can help WikiMD by expanding it!
